Aseptic loosening of total joint replacements: mechanisms underlying osteolysis and potential therapies

Harris WH: The problem is osteolysis. Clin Orthop Rel Res. 1995, 311: 46-53. Kadoya Y, Kobayashi A, Ohashi H: Wear and osteolysis in total joint replacements. Acta Orthop Scand. 1998, 69: 1-16. Maloney W, Smith R: Periprosthetic osteolysis in total hip arthroplasty: the role of particulate waer debris. J Bone Joint Surg. 1995, 77A: 1448-1461. Crotti TN, Smith MD, Findlay DM, Zreiqat H, Ahern MJ, Weedon H, Hatzinikolous G, Capone M, Holding C, Haynes DR: Factors regulating osteoclast formation in human tissues adjacent to peri-implant bone loss: expression of receptor activator NFkappaB, RANK ligand and osteoprotegerin. Biomaterials. 2004, 25: 565-573. 10.1016/S0142-9612(03)00556-8. Gehrke T, Sers C, Morawietz L, Fernahl G, Neidel J, Frommelt L, Krenn V: Receptor activator of nuclear factor kappaB ligand is expressed in resident and inflammatory cells in aseptic and septic prosthesis loosening. Scand J Rheumatol. 2003, 32: 287-294. 10.1080/03009740310003929. Khosla S: Minireview: the OPG/RANKL/RANK system. Endocrinology. 2001, 142: 5050-5055. 10.1210/en.142.12.5050. Abu-Amer Y: Advances in osteoclast differentiation and function. Curr Drug Targets Immune Endocr Metabol Disord. 2005, 5: 347-355. 10.2174/1568008054863808. Goldring SR, Clark CR, Wright TM: The problem in total joint arthroplasty: aseptic loosening. J Bone Joint Surg. 1993, 75A: 799-801. Gonzalez O, Smith RL, Goodman SB: Effect of size, concentration, surface area, and volume of polymethylmethacrylate particles on human macrophages in vitro. J Biomed Mater Res. 1996, 30: 463-473. 10.1002/(SICI)1097-4636(199604)30:4<463::AID-JBM4>3.0.CO;2-N. Sabokbar A, Pandey R, Athanasou NA: The effect of particle size and electrical charge on macrophage-osteoclast differentiation and bone resorption. J Mater Sci Mater Med. 2003, 14: 731-738. 10.1023/A:1025088418878. Gelb H, Schumacher HR, Cuckler J, Baker DG: In vivo inflammatory response to polymethylmethacrylate particulate debris: effect of size, morphology, and surface area. J Ortho Res. 1994, 12: 83-92. 10.1002/jor.1100120111. Shanbhag AS, Jacobs JJ, Glant TT, Gilbert JL, Black J, Galante JO: Composition and morphology of wear debris in failed uncemented total hip replacement. J Bone Joint Surg Br. 1994, 76: 60-67. Abbas S, Clohisy JC, Abu-Amer Y: Mitogen-activated protein (MAP) kinases mediate PMMA-induction of osteoclasts. J Orthop Res. 2003, 21: 1041-1048. 10.1016/S0736-0266(03)00081-0. O'Keefe RJ, Rosier RN, Teot LA, Stewart JM, Hicks DG: Cytokine and matrix metalloproteinase expression in pigmented villonodular synovitis may mediate bone and cartilage destruction. Iowa Orthop J. 1998, 18: 26-34. Gallo J, Kamâinek P, Tichâa V, Rihâakovâa P, Ditmar R: Particle disease. A comprehensive theory of periprosthetic osteolysis: a review. Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub. 2002, 146: 21-28. Ulrich-Vinther M, Carmody EE, Goater JJ, Sballe K, O'Keefe RJ, Schwarz EM: Recombinant adeno-associated virus-mediated osteoprotegerin gene therapy inhibits wear debris-induced osteolysis. J Bone Joint Surg. 2002, 84: 1405- Goldring SR: Bone and joint destruction in rheumatoid arthritis: what is really happening?. J Rheumatol Suppl. 2002, 65: 44-48. Clohisy JC, Calvert G, Tull F, McDonald D, Maloney WJ: Reasons for revision hip surgery: a retrospective review. Clin Orthop Relat Res. 2004, 429: 188-192. 10.1097/01.blo.0000150126.73024.42. Voloshin I, Gelinas J, Maloney MD, O'Keefe RJ, Bigliani LU, Blaine TA: Proinflammatory cytokines and metalloproteases are expressed in the subacromial bursa in patients with rotator cuff disease. Arthroscopy. 2005, 21: 1076- Shanbhag AS, Bailey HO, Hwang DS, Cha CW, Eror NG, Rubash HE: Quantitative analysis of ultrahigh molecular weight polyethylene (UHMWPE) wear debris associated with total knee replacements. J Biomed Mater Res. 2000, 53: 100-110. 10.1002/(SICI)1097-4636(2000)53:1<100::AID-JBM14>3.0.CO;2-4. Jacobs JJ, Hallab NJ, Urban RM, Wimmer MA: Wear particles. J Bone Joint Surg Am. 2006, 99-102. 10.2106/JBJS.F.00102. Suppl 2 Shanbhag AS, Jacobs JJ, Glant TT, Gilbert JL, Black J, Galante JO: Composition and morphology of wear debris in failed uncemented total hip replacement. J Bone Joint Surg Br. 1994, 76: 60-67. Shanbhag AS, Jacobs JJ, Black J, Galante JO, Glant TT: Cellular mediators secreted by interfacial membranes obtained at revision total hip arthroplasty. J Arthroplasty. 1995, 10: 498-506. 10.1016/S0883-5403(05)80152-4. Hirakawa K, Jacobs JJ, Urban R, Saito T: Mechanisms of failure of total hip replacements: lessons learned from retrieval studies. Clin Orthop Relat Res. 2004, 420: 10-17. 10.1097/00003086-200403000-00003. Shanbhag AS, Jacobs JJ, Black J, Galante JO, Glant TT: Effects of particles on fibroblast proliferation and bone resorption in vitro. Clin Orthop Relat Res. 1997, 342: 205-217. 10.1097/00003086-199709000-00028. Purdue PE, Koulouvaris P, Potter HG, Nestor BJ, Sculco TP: The cellular and molecular biology of periprosthetic osteolysis. Clin Orthop Relat Res. 2007, 454: 251-261. 10.1097/01.blo.0000238813.95035.1b. Chambers TJ: The cellular basis of bone resorption. Clin Orthop. 1980, 151: 283-293. Arora A, Song Y, Chun L, Huie P, Trindade M, Smith RL, Goodman S: The role of the TH1 and TH2 immune responses in loosening and osteolysis of cemented total hip replacements. J Biomed Mater Res A. 2003, 64: 693-697. 10.1002/jbm.a.10200. Farber A, Chin R, Song Y, Huie P, Goodman S: Chronic antigen-specific immune-system activation may potentially be involved in the loosening of cemented acetabular components. J Biomed Mater Res. 2001, 55: 433-441. 10.1002/1097-4636(20010605)55:3<433::AID-JBM1033>3.0.CO;2-N. Goodman SB: Does the immune system play a role in loosening and osteolysis of total joint replacements?. J Long Term Eff Med Implants. 1996, 6: 91-101. Groot D, Gosens T, Leeuwen NC, Rhee MV, Teepen HJ: Wear-induced osteolysis and synovial swelling in a patient with a metal-polyethylene wrist prosthesis. J Hand Surg. 2006, 31: 1615-1618. 10.1016/j.jhsa.2006.09.009. Hallab NJ, Anderson S, Stafford T, Glant T, Jacobs JJ: Lymphocyte responses in patients with total hip arthroplasty. J Orthop Res. 2005, 23: 384-391. 10.1016/j.orthres.2004.09.001. Hallab NJ, Anderson S, Stafford T, Glant T, Jacobs JJ: Lymphocyte responses in patients with total hip arthroplasty. J Orthop Res. 2005, 23: 384-391. 10.1016/j.orthres.2004.09.001. Lam J, Abu-Amer Y, Nelson C, Fermont D, Ross F, Teitelbaum S: Tumor necrosis factor superfamily cytokines and the pathogenesis of inflammatory osteolysis. Ann Rheum Dis. 2002, 61: 82-83. 10.1136/ard.61.1.82. Quinn J, Joyner C, Triffitt JT, Athanasou NA: Polymethylmethacrylate-induced inflammatory macrophages resorb bone. J Bone Joint Surg Br. 1992, 74: 652-658. Sabokbar A, Itonaga I, Sun SG, Kudo O, Athanasou NA: Arthroplasty membrane-derived fibroblasts directly induce osteoclast formation and osteolysis in aseptic loosening. J Orthop Res. 2005, 23: 511-519. 10.1016/j.orthres.2004.10.006. Schwarz EM, O'Keefe RJ, Looney RJ: Bone implant interface, osteolysis and potential therapies. J Musculoskelet Neuronal Interact. 2004, 4: 390-392. Ritchlin CT, Schwarz EM, O'Keefe RJ, Looney RJ: RANK, RANKL and OPG in inflammatory arthritis and periprosthetic osteolysis. J Musculoskelet Neuronal Interact. 2004, 4: 276-284. Clohisy J, Hirayama T, Frazier E, Han S, Abu-Amer Y: NF-κB signaing blockade abolishes implant particle-induced osteoclastogenesis. J Orthop Res. 2004, 22: 13-20. 10.1016/S0736-0266(03)00156-6. Abu-Amer Y: Mechanisms of inflammatory mediators in bone loss diseases. Molecular Biology in Orthopedics. Edited by: Rosier RN, Evans CH. 2003, Rosemont, IL: American Academy of Orthopedic Surgeons, 229-239. Clohisy J, Teitelbaum S, Chen S, Erdmann J, Abu-Amer Y: TNF mediates PMMA particle-induced NF-κB activation in osteoclast precursor cells. J Orthop Res. 2002, 20: 174-181. 10.1016/S0736-0266(01)00088-2. Archibeck MJ, Jacobs JJ, Roebuck KA, Glant TT: The basic science of periprosthetic osteolysis. Instr Course Lect. 2001, 50: 185-195. Neale SD, Athanasou NA: Cytokine receptor profile of arthroplasty macrophages, foreign body giant cells and mature osteoclasts. Acta Orthop Scand. 1999, 70: 452-458. Perry MJ, Mortuza FY, Ponsford FM, Elson CJ, Atkins RM: Analysis of cell types and mediator production from tissues around loosening joint implants. Br J Rheumatol. 1995, 34: 1127-1134. 10.1093/rheumatology/34.12.1127. Shanbhag AS, Jacobs JJ, Black J, Galante JO, Glant TT: Cellular mediators secreted by interfacial membranes obtained at revision total hip arthroplasty. J Arthroplasty. 1995, 10: 498-506. 10.1016/S0883-5403(05)80152-4. Mundy GR: Mechanisms of osteolytic bone destruction. Bone. 1991, S1-S6. 10.1016/8756-3282(91)90057-P. Suppl 1 Schwarz E, Lu P, Goater J, Benz E, Kollias G, Rosier R, Puzas J, O'Keefe R: TNF-α/NF-κB signaling in periprosthetic osteolysis. J Orthop Res. 2000, 18: 472-480. 10.1002/jor.1100180321. Looney RJ, Schwarz EM, Boyd A, O'Keefe RJ: Periprosthetic osteolysis: an immunologist's update. Curr Opin Rheumatol. 2006, 18: 80-87. 10.1097/01.bor.0000198004.88568.96. Lacey DL, Timms E, Tan HL, Kelley MJ, Dunstan CR, Burgess T, Elliott R, Colombero A, Elliott G, Scully S, et al: Osteoprotegerin ligand is a cytokine that regulates osteoclast differentiation and activation. Cell. 1998, 93: 165-176. 10.1016/S0092-8674(00)81569-X. Simonet W, Lacey DL, Dunstan CR, Kelly M, Chang M, Nguyen S, Wooden S, Bennett L, Boone G: Osteoprotegerin: a novel secreted protein involved in the regulation of bone density. Cell. 2001, 89: 309-319. 10.1016/S0092-8674(00)80209-3. Teitelbaum S: Bone resorption by osteoclasts. Science. 2000, 289: 1504-1508. 10.1126/science.289.5484.1504. Childs L, Paschalis E, Xing L, Dougall W, Anderson D, Bosky A, Puzas J, Rosier R, O'Keefe R, Boyce B, et al: In vivo RANK signaling blockade using the receptor activator of NF-κB:Fc effectively prevents and ameliorates wear debris-induced osteolysis via osteoclast depletion without inhibiting osteogenesis. J Bone Miner Res. 2002, 17: 192-199. 10.1359/jbmr.2002.17.2.192. Zhang Y, Heulsmann A, Tondravi M, Mukherjee A, Abu-Amer Y: Tumor necrosis factor-alpha (TNF) stimulates RANKL-induced osteoclastogenesis via coupling of TNF type I receptor and RANK signaling pathways. J Biol Chem. 2000, 276: 563-568. 10.1074/jbc.M008198200. Kobayashi K, Takahashi N, Jimi E, Udagawa N, Takami M, Kotake S, Nakagawa N, Shima N, Yasuda H, Higashio K, et al: Tumor necrosis factor alpha stimulates osteoclast differentiation by a mechanism independent of the ODF/RANKL-RANK interaction. J Exp Med. 2000, 191: 275-285. 10.1084/jem.191.2.275. Abbas S, Abu-Amer Y: Dominant-negative IkB facilitates apoptosis of osteoclasts by tumor necrosis factor-α. J Biol Chem. 2003, 278: 20077-20082. 10.1074/jbc.M208619200. Zreiqat H, Crotti TN, Howlett CR, Capone M, Markovic B, Haynes DR: Prosthetic particles modify the expression of bone-related proteins by human osteoblastic cells in vitro. Biomaterials. 2003, 24: 337-346. 10.1016/S0142-9612(02)00324-1. Wei X, Zhang X, Zuscik MJ, Drissi MH, Schwarz EM, O'Keefe RJ: Fibroblasts express RANKL and support osteoclastogenesis in a COX-2-dependent manner after stimulation with titanium particles. J Bone Miner Res. 2005, 20: 1136-1148. 10.1359/JBMR.050206. Abu-Amer Y, Faccio R: Therapeutic approaches in bone pathogeneses: targeting the IKK/NF-κB axis. Future Rheumatol. 2006, 1: 133-146. 10.2217/17460816.1.1.133. Ulrich-Vinther M, Carmody EE, Goater JJ, Sballe K, O'Keefe RJ, Schwarz EM: Recombinant adeno-associated virus-mediated osteoprotegerin gene therapy inhibits wear debris-induced osteolysis. J Bone Joint Surg Am. 2002, 84-A: 1405-1412. Clohisy J, Roy B, Biondo C, Frazier E, Willis D, Teitelbaum S, Abu-Amer Y: Direct inhibition of NF-κB blocks bone erosion associated with inflammatory arthritis. J Immunol. 2003, 171: 5547-5553. Dai S, Hirayama T, Abbas S, Abu-Amer Y: The IκB kinase (IKK) inhibitor, NEMO-binding domain peptide, blocks osteoclastogenesis and bone erosion in inflammatory arthritis. J Biol Chem. 2004, 279: 37219-37222. 10.1074/jbc.C400258200. Abu-Amer Y, Faccio R: Therapeutic approaches in bone pathogeneses: targeting the IKK/NF-κB axis. Future Med. 2006, 1: 133-146. Susva M, Missbach M, Green J: Src inhibitors: drugs for the treatment of osteoporosis, cancer or both?. Trends Pharmacol Sci. 2000, 21: 489-495. 10.1016/S0165-6147(00)01567-4. Violette S, Guan W, Bartlett C, Smith J, Bardelay C, Antoine E, Rickles R, Mandine E, Adams S, Lynch B, et al: Bone-targeted src SH2 inhibitors block src cellular activity and osteoclast-mediated resorption. Bone. 2001, 28: 54-64. 10.1016/S8756-3282(00)00427-0. Goldring SR, Gravallese EM: Bisphosphonates: environmental protection for the joint?. Arthritis Rheum. 2004, 50: 2044-2047. 10.1002/art.20383. Sato M, Grasser W: Effects of bisphosphonates on isolated rat osteoclasts as examined by reflected light microscopy. J Bone Miner Res. 1990, 5: 31-40. Carano A, Teitelbaum SL, Konsek JD, Schlesinger PH, Blair HC: Bisphosphonates directly inhibit the bone resorption activity of isolated avian osteoclasts in vitro. J Clin Invest. 1990, 85: 456-461. 10.1172/JCI114459. Sato M, Grasser W, Endo N, Akins R, Simmons H, Thompson DD, Golub E, Rodan GA: Bisphosphonate action. Alendronate localization in rat bone and effects on osteoclast ultrastructure. J Clin Invest. 1991, 88: 2095-2105. 10.1172/JCI115539. Seedor JG, Quartuccio HA, Thompson DD: The bisphosphonate alendronate (MK-217) inhibits bone loss due to ovariectomy in rats. J Bone Miner Res. 1991, 6: 339-346. Balena R, Toolan BC, Shea M, Markatos A, Myers ER, Lee SC, Opas EE, Seedor JG, Klein H, Frankenfield D, et al: The effects of 2-year treatment with the aminobisphosphonate alen-dronate on bone metabolism, bone histomorphometry, and bone strength in ovariectomized nonhuman primates. J Clin Invest. 1993, 93: 2577-2586. 10.1172/JCI116872. Millett PJ, Allen MJ, Bostrom MPG: Effects of alendronate on particle-induced osteolysis in a rat model. J Bone Joint Surg. 2002, 84: 236- van de Loo FA, van den Berg WB: Gene therapy for rheumatoid arthritis. Lessons from animal models, including studies on interleukin-4, interleukin-10, and interleukin-1 receptor antagonist as potential disease modulators. Rheum Dis Clin North Am. 2002, 28: 127-149. 10.1016/S0889-857X(03)00073-5. Woods J, Katschke JK, Volin M, Ruth J, Woodruff D, Amin M, Connors M, Kurata H, Arai K, Haines IG: IL-4 adenoviral gene therapy reduces inflammation, proinflammatory cytokines, vascularization, and bony destruction in rat adjuvant-induced arthritis. J Immunol. 2001, 166: 1214-1222. Takeda K, Tanaka T, Shi W, Matsumoto M, Minami M, Kashiwamura S, Nakanishi K, Yoshida N, Kishimoto T, Akira S: Essential role of Stat6 in IL-4 signalling. Nature. 1996, 380: 627-630. 10.1038/380627a0. Abu-Amer Y: IL-4 abrogates osteoclastogenesis through STAT6-dependent inhibition of NF-κB. J Clin Invest. 2001, 107: 1375-1385. 10.1172/JCI10530. Takayanagi H, Kim S, Matsuo K, Suzuki H, Suzuki T, Sato K, Yokochi T, Oda H, Nakamura K, Ida N, et al: RANKL maintains bone homeostasis through c-Fos-dependent induction of interferon-beta. Nature. 2002, 416: 744-749. 10.1038/416744a.